基石药业-B(02616)将携CS2015(OX40L/TSLP双特异性抗体)亮相ACAAI 2025

智通财经
Sep 15

智通财经APP讯,基石药业-B(02616)发布公告,公司自身免疫与炎症领域管线之一CS2015(OX40L/TSLP双特异性抗体)入选2025年美国过敏,哮喘和免疫学会(ACAAI)年度科学会议,并将以“电子壁报演示+现场口头汇报”的形式展出。本次大会将于11月6日至10日在美国奥兰多举行。

CS2015是一款同时靶向OX40L和TSLP的潜在同类首创/同类最佳双特异性抗体,通过双重抑制 Th2介导炎症反应的关键调控因子,为特应性皮炎(AD)、哮喘、慢性阻塞性肺病(COPD)等2型炎症性疾病提供新治疗策略。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10